Cue Biopharma (CUE)

Currency in USD
35.350
+1.960(+5.87%)
Closed·
35.390+0.040(+0.11%)
·
CUE is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
30.92036.990
52 wk Range
4.97141.420
Key Statistics
Prev. Close
33.39
Open
32.34
Day's Range
30.92-36.99
52 wk Range
4.971-41.42
Volume
185.49K
Average Volume (3m)
706.84K
1-Year Change
50.4319%
Book Value / Share
6.64
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CUE Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
115.000
Upside
+225.32%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Cue Biopharma News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 115.000
(+225.32% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Citizens
Buy2.00-94.34%-MaintainNov 18, 2025
Lucid Capital Markets
Buy4.00-88.68%-New CoverageAug 25, 2025

Cue Biopharma SWOT Analysis


Strategic Pivot
Cue Biopharma's shift from oncology to autoimmune diseases reshapes its market position and pipeline, sparking debate on future growth potential
Financial Outlook
With a $41M cash position and restructuring efforts, Cue Biopharma aims to extend its runway into mid-2025, balancing innovation with fiscal prudence
Pipeline Promise
Explore Cue's evolving portfolio, including CUE-401 and CUE-501, as it targets autoimmune diseases with novel immunotherapies and potential off-the-shelf alternatives
Market Dynamics
Analysts project price targets ranging from $2 to $15, reflecting varied perspectives on Cue's strategic shift and competitive positioning in the autoimmune secto
Read full SWOT analysis

Cue Biopharma Earnings Call Summary for Q4/2023

  • CUE-101 and CUE-102 show promise in cancer treatment, with CUE-101 advancing to Phase 2 study for HPV+ head and neck cancer
  • Collaboration revenue of $1.8M for Q4 2023, primarily from Ono Pharmaceuticals partnership; $48.5M cash on hand as of Dec 31, 2023
  • Company seeks strategic partnerships to enhance development capacity and capital access for oncology and autoimmune programs
  • CUE-401 and CUE-500 series demonstrate potential in restoring immune balance for autoimmune diseases
  • Data presentations scheduled for ASCO, including longer follow-up and results from ~35 patients in CUE-101-01 and CUE-102 trials
Last Updated: 2024-04-09, 04:36 p/m
Read Full Transcript

Earnings

Latest Release
May 14, 2026
EPS / Forecast
-1.08 / -3.30
Revenue / Forecast
5.69M / 2.5M
EPS Revisions
Last 90 days

CUE Income Statement

Compare CUE to Peers and Sector

Metrics to compare
CUE
Peers
Sector
Relationship
P/E Ratio
−7.6x−4.2x−0.4x
PEG Ratio
−0.10−0.110.00
Price/Book
6.9x2.6x2.6x
Price / LTM Sales
4.5x8.9x3.0x
Upside (Analyst Target)
244.4%141.3%51.9%
Fair Value Upside
Unlock0.3%9.4%Unlock

Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company’s lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases. It also developed the Immuno-STAT platform, which targets disease-specific T cells in vivo without broad immune modulation. The company’s lead autoimmune candidate is CUE-401, a bifunctional IL-2 and TGF-B program that is advancing towards Phase 1 development to regulate inflammation and drive Treg-mediated tolerance. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
195.24K4.83%6.34M
Other Institutional Investors
2.62M15.16%85.14M
Public Companies & Retail Investors
11.27M80.01%366.26M
Total
14.09M100.00%457.75M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Bleichroeder LP5.62%227,3057,386
Catalytic Wealth RIA, LLC3.82%154,3875,017

People Also Watch

98.34
SOIT
+0.18%
10.1600
AKAN
-11.03%
4.090
ICCM
-2.15%
0.5559
NEXR
-2.56%
30.64
TNGX
+1.73%

FAQ

What Is the Cue Biopharma (CUE) Stock Price Today?

The Cue Biopharma stock price today is 35.350 USD.

What Stock Exchange Does Cue Biopharma Trade On?

Cue Biopharma is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Cue Biopharma?

The stock symbol for Cue Biopharma is "CUE."

What Is the Cue Biopharma Market Cap?

As of today, Cue Biopharma market cap is 151.760M USD.

What Is Cue Biopharma's Earnings Per Share (TTM)?

The Cue Biopharma EPS (TTM) is -5.219.

When Is the Next Cue Biopharma Earnings Date?

Cue Biopharma will release its next earnings report on Aug 18, 2026.

From a Technical Analysis Perspective, Is CUE a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Cue Biopharma Stock Split?

Cue Biopharma has split 1 times.

How Many Employees Does Cue Biopharma Have?

Cue Biopharma has 29 employees.

What is the current trading status of Cue Biopharma (CUE)?

As of Jul 09, 2026, Cue Biopharma (CUE) is trading at a price of 35.350 USD, with a previous close of 33.390 USD. The stock has fluctuated within a day range of 30.920 USD to 36.990 USD, while its 52-week range spans from 4.971 USD to 41.420 USD.

What Is Cue Biopharma (CUE) Price Target According to Analysts?

The average 12-month price target for Cue Biopharma is 115.000 USD, with a high estimate of 115 USD and a low estimate of 115 USD. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +225.32% Upside potential.

What Is the CUE Premarket Price?

CUE's last pre-market stock price is 32.310 USD. The pre-market share volume is 119.000, and the stock has decreased by -1.080, or -3.230%.

What Is the CUE After Hours Price?

CUE's last after hours stock price is 35.390 USD, the stock has decreased by 0.040, or 0.110%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.